BMY vs. JNJ, ABBV, MRK, PFE, ZTS, RPRX, CORT, JAZZ, PRGO, and SUPN
Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Zoetis (ZTS), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "pharmaceuticals" industry.
Bristol-Myers Squibb vs.
Bristol-Myers Squibb (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership.
In the previous week, Johnson & Johnson had 34 more articles in the media than Bristol-Myers Squibb. MarketBeat recorded 73 mentions for Johnson & Johnson and 39 mentions for Bristol-Myers Squibb. Johnson & Johnson's average media sentiment score of 1.38 beat Bristol-Myers Squibb's score of 1.12 indicating that Johnson & Johnson is being referred to more favorably in the news media.
Bristol-Myers Squibb pays an annual dividend of $2.48 per share and has a dividend yield of 5.0%. Johnson & Johnson pays an annual dividend of $5.20 per share and has a dividend yield of 3.3%. Bristol-Myers Squibb pays out 92.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson pays out 57.8% of its earnings in the form of a dividend. Bristol-Myers Squibb has raised its dividend for 17 consecutive years and Johnson & Johnson has raised its dividend for 64 consecutive years.
Johnson & Johnson received 38 more outperform votes than Bristol-Myers Squibb when rated by MarketBeat users. However, 65.96% of users gave Bristol-Myers Squibb an outperform vote while only 64.74% of users gave Johnson & Johnson an outperform vote.
Bristol-Myers Squibb has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.
Johnson & Johnson has higher revenue and earnings than Bristol-Myers Squibb. Johnson & Johnson is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.
Johnson & Johnson has a net margin of 18.20% compared to Bristol-Myers Squibb's net margin of -18.53%. Johnson & Johnson's return on equity of 34.24% beat Bristol-Myers Squibb's return on equity.
Bristol-Myers Squibb presently has a consensus price target of $58.00, indicating a potential upside of 16.10%. Johnson & Johnson has a consensus price target of $170.88, indicating a potential upside of 9.23%. Given Bristol-Myers Squibb's higher possible upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Johnson & Johnson.
76.4% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by company insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Johnson & Johnson beats Bristol-Myers Squibb on 17 of the 21 factors compared between the two stocks.
Get Bristol-Myers Squibb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bristol-Myers Squibb Competitors List
Related Companies and Tools
This page (NYSE:BMY) was last updated on 6/11/2025 by MarketBeat.com Staff
